Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489166 | 0.89 | POLB (0.59) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL25523588 | 0.88 | CYP1A2 (0.55) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL25523590 | 0.86 | KDM4E (0.56) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL31289581 | 0.85 | KDM4E (0.58) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL31289580 | 0.85 | KDM4E (0.58) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL12527449 | 0.85 | KDM4E (0.58) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL30524343 | 0.85 | KDM4E (0.58) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL29559196 | 0.82 | KDM4E (0.54) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL25523741 | 0.82 | KDM4E (0.54) | CYP1A2BACE1KDM4EGAASMN1; SMN2 | |
| SCHEMBL30511679 | 0.80 | POLB (0.47) | CYP1A2BACE1KDM4EGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2008048967-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | CA14, HCAR1, CCKAR | CYP1A2 4569/4885BACE1 3949/4885KDM4E 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.